Sign in
Taking peopleNo phase

Looking for muscle loss in women with gestational diabetes

Checks for sarcopenia and its effects in pregnant women with gestational diabetes.

Key facts

Who runs it
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
Where
Austria and Italy3 sites in 2 countriesChoose a country to see its sites
Trial code
Registry title
Sarcopenia in Gestational Diabetes
Status
Recruiting
People taking part
200 people, planned
Started
28 May 2025
Planned end
Apr 2026
Type of study
Observational, 2 groups
Treatments tested
  • Sarcopenia tests (for muscle mass, muscle function, physical performance)
  • Oral Glucose Tolerance Test
  • Montreal Cognitive Assessment
Record updated
21 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women, with or without gestational diabetes (diabetes that starts in pregnancy). It checks for muscle loss (sarcopenia), and looks at memory and thinking.

Age
The record lists 35 years or older. The criteria also say age 35 years or older is one of several ways to join.
Sex
Women only.
Disease stage
Women must have at least one of these: age 35 years or older; BMI 25 kg/m^2 or higher; blood sugar between 5.6 and 6.9 mmol/L (101–124 mg/dL) before or early in pregnancy; a very large baby in an earlier pregnancy; gestational diabetes in an earlier pregnancy; a parent, brother, sister or child with diabetes.
Biomarker or test result
One possible way to join is blood sugar between 5.6 and 6.9 mmol/L (101–124 mg/dL) before or at the beginning of pregnancy.

Main reasons for not taking part

  • Women who have none of the conditions listed to join cannot join
  • Pregnancy with twins
  • A known disease that may affect muscle mass or strength
  • Diseases of the brain and nerves, or mental health conditions
  • Diabetes already known before, such as type 1 or type 2

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • At least one among the following conditions:
  • Age equal to or higher than 35 years
  • Body mass index (BMI) equal to or higher than 25 kg/m\^2
  • Glycemia between 5.6 and 6.9 mmol/L before or at the beginning of pregnancy
  • Fetal macrosomia in previous pregnancy
  • GDM in previous pregnancy
  • First-degree family history of diabetes

Who cannot take part

  • Presence of any already known disease/disorder possibly affecting muscle mass or function
  • Neurological or psychiatric diseases
  • Already known diabetes (e.g., type 1 or type 2 diabetes)
  • Unmatching of at least one among the inclusion criteria
  • Twin pregnancy

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:

Read full original descriptionShow less

1. To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence; 2. To identify risk factors for sarcopenia; 3. To determine sarcopenia impact on pregnancy outcomes, and cognitive function.

During pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia/presarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.

The 2 groups in the trial

  • Gestational diabetes (GDM) women

    Treatment: Sarcopenia tests (for muscle mass, muscle function, physical performance), Oral Glucose Tolerance Test, and Montreal Cognitive Assessment

  • Pregnant women without gestational diabetes (non-GDM)

    Treatment: Sarcopenia tests (for muscle mass, muscle function, physical performance), Oral Glucose Tolerance Test, and Montreal Cognitive Assessment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sarcopenia in Gestational Diabetes: The SiGnal-D Study
Plain-language title
Looking for muscle loss in women with gestational diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Publications
Record updated
21 November 2025